Shoko Kagawa

Effects of Genetic Polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia

Takeshi Suzuki, Kazuo Mihara, A. Nakamura et al. · Therapeutic Drug Monitoring · 2014 · 57 citations

Medicine, Pharmacokinetics, Pharmacology +17

Effects of the CYP2D6*10 Allele on the Steady-State Plasma Concentrations of Aripiprazole and Its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia

Takeshi Suzuki, Kazuo Mihara, A. Nakamura et al. · Therapeutic Drug Monitoring · 2010 · 43 citations

Medicine, Pharmacokinetics, Pharmacology +16

Relationship Between Plasma Concentrations of Lamotrigine and Its Early Therapeutic Effect of Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder

Shoko Kagawa, Kazuo Mihara, A. Nakamura et al. · Therapeutic Drug Monitoring · 2014 · 31 citations

Medicine, Pharmacology, Psychiatry +17

Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of<i>dopamine<scp>D</scp>2 receptor</i>and<i>cytochrome<scp>P</scp>450 2<scp>D</scp>6</i>in Japanese patients with schizophrenia

Goyo Nagai, Kazuo Mihara, A. Nakamura et al. · Psychiatry and Clinical Neurosciences · 2012 · 29 citations · Full text

Medicine, Pharmacology, Psychiatry +17

Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy

Takeshi Suzuki, Kazuo Mihara, Goyo Nagai et al. · Therapeutic Drug Monitoring · 2018 · 20 citations

Medicine, Pharmacology, Psychiatry +17